Hoffmann, Friederike
Franzen, Alina
de Vos, Luka
Wuest, Lennert
Kulcsár, Zsófi
Fietz, Simon
Maas, Alexander Philippe
Hollick, Sarah
Diop, Marie Yatou
Gabrielpillai, Jennis
Vogt, Timo
Kuster, Pia
Zarbl, Romina
Dietrich, Joern
Kristiansen, Glen
Brossart, Peter
Landsberg, Jennifer
Strieth, Sebastian
Dietrich, Dimo
Funding for this research was provided by:
Deutsche Krebshilfe (70113307)
University Medical Center Bonn BONFOR program (2022-1A-08, 2020-1A-13, 2020-2A-06, 2022-4-18, 2023-4-06, 2022-1A-08, 2020-1A-13, 2020-2A-06, 2022-4-18, 2023-4-06, 2022-1A-08, 2020-1A-13, 2020-2A-06, 2022-4-18, 2023-4-06, 2022-1A-08, 2020-1A-13, 2020-2A-06, 2022-4-18, 2023-4-06, 2022-1A-08, 2020-1A-13, 2020-2A-06, 2022-4-18, 2023-4-06)
Universitätsklinikum Bonn
Article History
Received: 20 December 2022
Accepted: 25 June 2023
First Online: 6 July 2023
Declarations
:
: Patient inclusion and sample analyses at the University Hospital Bonn were approved by the Institutional Review Board (IRB) of the University Hospital Bonn (vote 187/16). Informed consent was obtained from all individual participants included in the study.
: JL is a consultant / advisory board member of Merck Sharp & Dohme, Novartis, and Roche. DD is inventor and owns granted and pending patents (e.g. PCT/EP2016/001237, WO/2017/008912, DE102015009187A, PCT/EP2018/080073, WO/2019/086642, DE102017125780, WO/2017/198617, PCT/EP2017/061612, DE102016005947). The patents are licensed by Qiagen GmbH (Hilden, Germany) and DD receives royalties by Qiagen. The remaining authors have declared that there are no financial conflicts of interest with regard to this work.